ARCHIVES

Early ADT Doesn’t Offer Survival Advantage—ASCO

This article is from The Cancer Letter archive.

Vol. 30 No. 4 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

January 25, 2013

In Brief: Friedell To Head McDowell Network, New Kentucky Cancer Center; Nine Expiring Core Grants Approved

October 29, 1982

Seer Gets Concept Approval For Three More Years, With Several Changes

June 19, 1981

AACI Asks NCI to Reconsider Dropping CCPDS Support, Find New Mechanism to Fund Center Outreach Effort

July 9, 1982

The Duke Scandal: NEJM Retracts Potti Paper

March 4, 2011

CMS Issues Coverage Decision For Provenge in Prostate Cancer

July 29, 2011